Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML Sutro Biopharma, Inc. Fri, Nov 1, 2024, 8:00 AM 7 min read ...

“We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia,” said ...

“We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia,” said ...

“We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia ...

"We are excited to announce the initiation of our second pivotal trial, the registration-enabling clinical trial of luvelta in infants and toddlers with a rare and aggressive form of leukemia,” said ...

for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment. “We are excited to announce the initiation of our ...

Ointments have the advantage of increased dwell time in the eye, but often patients and parents of children prefer drops, and no therapeutic advantage of one over the other has been demonstrated.

If all emergency departments in the U.S. were fully prepared to treat children, about 25% of deaths that occur annually among pediatric patients receiving emergency care could be prevented ...

A suite of information for GP partners, practice managers and doctors to use to ensure your practice is compliant and delivering the best patient care. Safe working and managing workload in general ...